Loading clinical trials...
Loading clinical trials...
A Three Arm, Randomized, Double Blind, Placebo Controlled, Multicenter, Phase II Study to Evaluate the Efficacy of Vigantol® Oil as Add on Therapy in Subjects With Relapsing Remitting Multiple Sclerosis Receiving Treatment With 44mg Tiw of Rebif®
Conditions
Interventions
VigantOL oil plus interferon beta-1a (Rebif)
Placebo plus interferon beta-1a (Rebif)
+1 more
Locations
38
Austria
Research Site
Vienna, Austria
Research Site
Esbjerg, Denmark
Research Site
Glostrup Municipality, Denmark
Research Site
Sønderborg, Denmark
Research Site
Vejle, Denmark
Research Site
Viborg, Denmark
Start Date
February 1, 2011
Primary Completion Date
April 1, 2015
Completion Date
May 1, 2015
Last Updated
November 28, 2016
NCT05758831
NCT06586177
NCT05906992
NCT05755061
NCT01805336
NCT04940065
Lead Sponsor
Merck KGaA, Darmstadt, Germany
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions